肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2011年
1期
28-30
,共3页
任庆%伍靖武%熊锐华%周欣
任慶%伍靖武%熊銳華%週訢
임경%오정무%웅예화%주흔
肠肿瘤%药物疗法,联合%治疗
腸腫瘤%藥物療法,聯閤%治療
장종류%약물요법,연합%치료
Intestinal neoplasms%Drug therapy,combination%Therapy
目的 观察FOLFIRI方案二线治疗晚期大肠癌的临床疗效和不良反应.方法 病理确诊的44例晚期大肠癌患者接受FOLFIRI方案化疗:伊立替康(CPT-11)150mg/m2,静脉滴注,第1天;亚叶酸钙(CF)200mg/m2,静脉滴注2 h,第1、2天;5-氟尿嘧啶(5-Fu)400mg/m2,静脉注射,第1、2天后予5-Fu 600 mg/m2持续静脉滴注22 h,第1、2天;每2周重复,化疗2次为1个周期.治疗4~6个周期后按实体瘤疗效评定标准评价疗效及不良反应.结果 全组病例均可评价疗效,其中完全缓解2例,部分缓解16例,有效率为40.9%;中位生存期11.3个月,中位疾病进展时间6.5个月.主要的不良反应为乙酰胆碱能综合征和迟发性腹泻及骨髓抑制.结论 FOLFIRI方案作为二线方案治疗晚期大肠癌疗效肯定,可使大部分患者临床受益,不良反应可以耐受,值得临床进一步试用、研究.
目的 觀察FOLFIRI方案二線治療晚期大腸癌的臨床療效和不良反應.方法 病理確診的44例晚期大腸癌患者接受FOLFIRI方案化療:伊立替康(CPT-11)150mg/m2,靜脈滴註,第1天;亞葉痠鈣(CF)200mg/m2,靜脈滴註2 h,第1、2天;5-氟尿嘧啶(5-Fu)400mg/m2,靜脈註射,第1、2天後予5-Fu 600 mg/m2持續靜脈滴註22 h,第1、2天;每2週重複,化療2次為1箇週期.治療4~6箇週期後按實體瘤療效評定標準評價療效及不良反應.結果 全組病例均可評價療效,其中完全緩解2例,部分緩解16例,有效率為40.9%;中位生存期11.3箇月,中位疾病進展時間6.5箇月.主要的不良反應為乙酰膽堿能綜閤徵和遲髮性腹瀉及骨髓抑製.結論 FOLFIRI方案作為二線方案治療晚期大腸癌療效肯定,可使大部分患者臨床受益,不良反應可以耐受,值得臨床進一步試用、研究.
목적 관찰FOLFIRI방안이선치료만기대장암적림상료효화불량반응.방법 병리학진적44례만기대장암환자접수FOLFIRI방안화료:이립체강(CPT-11)150mg/m2,정맥적주,제1천;아협산개(CF)200mg/m2,정맥적주2 h,제1、2천;5-불뇨밀정(5-Fu)400mg/m2,정맥주사,제1、2천후여5-Fu 600 mg/m2지속정맥적주22 h,제1、2천;매2주중복,화료2차위1개주기.치료4~6개주기후안실체류료효평정표준평개료효급불량반응.결과 전조병례균가평개료효,기중완전완해2례,부분완해16례,유효솔위40.9%;중위생존기11.3개월,중위질병진전시간6.5개월.주요적불량반응위을선담감능종합정화지발성복사급골수억제.결론 FOLFIRI방안작위이선방안치료만기대장암료효긍정,가사대부분환자림상수익,불량반응가이내수,치득림상진일보시용、연구.
Objective To evaluate the anti-tumor activity and toxicity of FOLFIRI regimen in the treatment of patients with advanced colorectal cancer. Methods 22 patients with advanced colorectal cancer used Irinotecan combined with 5-Fu/CF regimen to chemotherapy. Regimen: CPT-11 150 mg/m2 iv drip d1, CF 200 mg/m2 iv drip 2 h d1, 2; 5-Fu 400 mg/m2 iv drip d1, 2; 5-Fu 600 mg/m2 iv drip 22 h d1, 2. It is repeated every 2 weeks, two times a course. Efficiency and toxicity was evaluated after 4-6 cycles. Results Forty four patients were evaluated the efficiency. Two patients achieved CR, 16 PR, response rate was 40.9 %; MST was 11.3 months. TTP was 6.5 months. The main toxicity was cholinergic syndrome and delayed diarrhea,myelosuppression. There were no deaths during treatment. Conclusion The effectiveness of FOLFIRI regimen was higher and side effects was minor in advanced colorectal cancer. It should be further used and studied.